Moderna and Merck report that a new mRNA anti-cancer vaccine under investigation used in combination with standard therapy to treat stage IV melanoma reduces risk of relapse compared to standard therapy alone.

Dr. Barry Dworkin

Medical Mythbusting Commentary for December 14, 2022

Moderna and Merck report that a new mRNA anti-cancer vaccine under investigation used in combination with standard therapy to treat stage IV melanoma reduces risk of relapse compared to standard therapy alone. Play Now | Play in Popup | Download

Source:
Experimental mRNA cancer vaccine with immunotherapy reduces risk of melanoma returning, preliminary study finds

Reference:

Awaiting data release and publication

Related posts:

  1. "Dear 16-year-old-me" video about melanoma has gone viral
  2. Melanoma risk directly affected by tanning bed UV exposure
  3. Melanoma recurrence rates 10 years after treatment reviewed
  4. Skin cancer numbers increasing in Canada
Bitnami